Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model

被引:52
|
作者
Hwee, Darren T. [1 ]
Kennedy, Adam [1 ]
Ryans, Julie [1 ]
Russell, Alan J. [1 ]
Jia, Zhiheng [1 ]
Hinken, Aaron C. [1 ]
Morgans, David J. [1 ]
Malik, Fady I. [1 ]
Jasper, Jeffrey R. [1 ]
机构
[1] Cytokinet Inc, San Francisco, CA 94080 USA
来源
PLOS ONE | 2014年 / 9卷 / 05期
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; TIME-COURSE; RILUZOLE; MUTATION; IGF-1; MICE;
D O I
10.1371/journal.pone.0096921
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease characterized by progressive motor neuron loss resulting in muscle atrophy, declining muscle function, and eventual paralysis. Patients typically die from respiratory failure 3 to 5 years from the onset of symptoms. Tirasemtiv is a fast skeletal troponin activator that sensitizes the sarcomere to calcium; this mechanism of action amplifies the response of muscle to neuromuscular input producing greater force when nerve input is reduced. Here, we demonstrate that a single dose of tirasemtiv significantly increases submaximal isometric force, forelimb grip strength, grid hang time, and rotarod performance in a female transgenic mouse model (B6SJL-SOD1(G93A)) of ALS with functional deficits. Additionally, diaphragm force and tidal volume are significantly higher in tirasemtiv-treated female B6SJL-SOD1(G93A) mice. These results support the potential of fast skeletal troponin activators to improve muscle function in neuromuscular diseases.
引用
收藏
页数:9
相关论文
共 26 条
  • [11] PRE-SYMPTOMATIC DETECTION OF CHRONIC MOTOR DEFICITS AND GENOTYPE PREDICTION IN CONGENIC B6.SOD1G93A ALS MOUSE MODEL
    Hayworth, C. R.
    Gonzalez-Lima, F.
    NEUROSCIENCE, 2009, 164 (03) : 975 - 985
  • [12] VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
    Andrews, Jinsy A.
    Cudkowicz, Merit E.
    Hardiman, Orla
    Meng, Lisa
    Bian, Amy
    Lee, Jacqueline
    Wolff, Andrew A.
    Malik, Fady I.
    Shefner, Jeremy M.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2018, 19 (3-4) : 259 - 266
  • [13] Alterations in fast-twitch muscle membrane conductance regulation do not explain decreased muscle function of SOD1G93A rats
    Leermakers, Pieter A.
    Skov, Martin
    Riisager, Anders
    Nielsen, Ole B.
    Pedersen, Thomas H.
    MUSCLE & NERVE, 2021, 64 (06) : 755 - 764
  • [14] Expression profile of pattern recognition receptors in skeletal muscle of SOD1(G93A) amyotrophic lateral sclerosis (ALS) mice and sporadic ALS patients
    Lehmann, S.
    Esch, E.
    Hartmann, P.
    Goswami, A.
    Nikolin, S.
    Weis, J.
    Beyer, C.
    Johann, S.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2018, 44 (06) : 606 - 627
  • [15] P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis
    Fabbrizio, Paola
    Apolloni, Savina
    Bianchi, Andrea
    Salvatori, Illari
    Valle, Cristiana
    Lanzuolo, Chiara
    Bendotti, Caterina
    Nardo, Giovanni
    Volonte, Cinzia
    BRAIN PATHOLOGY, 2020, 30 (02) : 272 - 282
  • [16] Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1G93A ALS mouse model
    Duan, Chunling
    Kang, Moorim
    Pan, Xiaojie
    Gan, Zubao
    Huang, Vera
    Li, Guanlin
    Place, Robert F.
    Li, Long-Cheng
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (01):
  • [17] EXOCYTOSIS AND MITOCHONDRIAL ULTRASTRUCTURE AND FUNCTION IN CHROMAFFIN CELLS OF THE SOD1G93A MOUSE MODEL OF ALS AT A PRE-DISEASE STAGE
    Mendez-Lopez, I
    Martinez-Ramirez, C.
    Prieto Simancas, P.
    Ronda del Corro, M.
    Saez Albendea, L.
    Villaverde Rebenaque, P.
    Garcia, A. G.
    Padin Nogueira, J. F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 34 - 34
  • [18] An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS
    Dong, Quan-xiu
    Zhu, Jie
    Liu, Shu-ying
    Yu, Xiao-lin
    Liu, Rui-tian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 65 : 413 - 421
  • [19] Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues
    Corti, S
    Locatelli, F
    Donadoni, C
    Guglieri, M
    Papadimitriou, D
    Strazzer, S
    Del Bo, R
    Comi, GP
    BRAIN, 2004, 127 : 2518 - 2532
  • [20] Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1G93A ALS mouse model
    Zhao, J.
    Cooper, L. T.
    Boyd, A. W.
    Bartlett, P. F.
    SCIENTIFIC REPORTS, 2018, 8